Search for: All records

Extended reality (XR) technologies are becoming increasingly pervasive, and may have capacity to help marginalized groups such as transgender people. Drawing from interviews with n = 18 creators of trans technology, we examined how XR technologies do and can support trans people. We uncovered a number of creative ways that XR technologies support trans experiences. Trans technology creators are designing augmented reality (AR) and virtual reality (VR) systems that help people explore trans identity, experience new types of bodies, educate about and display trans stories and curated trans content, manipulate the physical world, and innovate gender-affirming surgical techniques. Additionally, we show how considering XR as an analogy for trans identity helps us to think about the fluidity and fluctuation inherent in trans identity in new ways, which in turn enables envisioning technologies that can better support complex and changing identities. Despite XR’s potential for supporting trans people, current AR and VR systems face limitations that restrict their large-scale use, but as access to XR systems increase, so will their capacity to improve trans lives. 

Abstract In a community-based sample of seropositive adults (n = 1101), we found that seropositive individuals who lived with a known coronavirus disease 2019 (COVID-19) case exhibited higher blood anti–severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain immunoglobulin G concentrations and greater symptom severity compared to seropositive individuals who did not live with a known COVID-19 case. 

Abstract BackgroundConfidence in natural immunity after infection with severe acute respiratory syndrome coronavirus 2 is one reason for vaccine hesitancy. MethodsWe measured antibody-mediated neutralization of spike protein-ACE2 receptor binding in a large community-based sample of seropositive individuals who differed in severity of infection (N = 790). ResultsA total of 39.8% of infections were asymptomatic, 46.5% were symptomatic with no clinical care, 13.8% were symptomatic with clinical care, and 3.7% required hospitalization. Moderate/high neutralizing activity was present after 41.3% of clinically managed infections, in comparison with 7.9% of symptomatic and 1.9% of asymptomatic infections. ConclusionsPrior coronavirus disease 2019 infection does not guarantee a high level of antibody-mediated protection against reinfection in the general population.